Literature DB >> 18027228

Adaptive group sequential test for clinical trials with changing patient population.

Huaibao Feng1, Jun Shao, Shein-Chung Chow.   

Abstract

In clinical trials, a standard group sequential test with a fixed number of planned interim analyses is usually considered to assess the effect of a test treatment under study. The standard group sequential test is statistically valid under the assumption that the patient population remains unchanged from one interim analysis to another. In practice, however, this assumption is often not met because the trial may be modified after the review of the clinical data at interim. As a result, the original patient population may have changed to a similar but different patient population. In this paper, we consider changes in patient population related to some covariates of an on-going trial through a linear regression model. Under this model, we can make inference on the original target population based on additional data from the changed populations. A new group sequential test procedure that accounts for the effect of population changes is proposed. A simulation was performed to evaluate the performance of the proposed method. The results indicate that the type I error rate of the proposed test procedure is well preserved, while the type I error rate of the standard group sequential test is inflated as the population changes. Statistical powers of the proposed group sequential test are also presented.

Entities:  

Mesh:

Year:  2007        PMID: 18027228     DOI: 10.1080/10543400701645512

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  9 in total

1.  Confounding due to changing background risk in adaptively randomized trials.

Authors:  Ari M Lipsky; Sander Greenland
Journal:  Clin Trials       Date:  2011-05-24       Impact factor: 2.486

Review 2.  Cell therapy and satellite centers: the Cardiovascular Cell Therapy Research Network experience.

Authors:  Lemuel A Moyé; Timothy D Henry; Kenneth W Baran; Judy Bettencourt; Barb Bruhn-Ding; Emily Caldwell; Jeffrey Chambers; Kelly Flood; Judy Francescon; Sherry Bowman; Casey Kappenman; Biswajit Kar; Charles Lambert; Jody LaRock; Amir Lerman; Stacey Mazzurco; Rakesh Prashad; Ganesh Raveendran; Daniel Simon; Lynette Westbrook; Robert D Simari
Journal:  Contemp Clin Trials       Date:  2011-07-08       Impact factor: 2.226

3.  Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial.

Authors:  Jordan J Elm; Yuko Y Palesch; Gary G Koch; Vanessa Hinson; Bernard Ravina; Wenle Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

4.  Inference in response-adaptive clinical trials when the enrolled population varies over time.

Authors:  Massimiliano Russo; Steffen Ventz; Victoria Wang; Lorenzo Trippa
Journal:  Biometrics       Date:  2021-10-21       Impact factor: 1.701

5.  Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  J Pharm Bioallied Sci       Date:  2010-10

6.  Adaptive design clinical trials: Methodology, challenges and prospect.

Authors:  Rajiv Mahajan; Kapil Gupta
Journal:  Indian J Pharmacol       Date:  2010-08       Impact factor: 1.200

7.  Including non-concurrent control patients in the analysis of platform trials: is it worth it?

Authors:  Kim May Lee; James Wason
Journal:  BMC Med Res Methodol       Date:  2020-06-24       Impact factor: 4.615

Review 8.  Adaptive design methods in clinical trials - a review.

Authors:  Shein-Chung Chow; Mark Chang
Journal:  Orphanet J Rare Dis       Date:  2008-05-02       Impact factor: 4.123

9.  Designs for adding a treatment arm to an ongoing clinical trial.

Authors:  Maxine Bennett; Adrian P Mander
Journal:  Trials       Date:  2020-03-06       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.